Syndax Pharmaceuticals (SNDX) Payables (2015 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly Payables of $10.8 million for Q1 2026, up 7.92% year-over-year from $10.0 million in Q1 2025, and down 34.6% quarter-over-quarter from $16.6 million in Q4 2025.
Syndax Pharmaceuticals (SNDX) Payables (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Payables history runs 12 years deep, the most recent figure standing at $10.8 million for Q1 2026.
- In Q1 2026, Payables rose 7.92% year-over-year to $10.8 million; the TTM figure through Mar 2026 stood at $10.8 million (up 7.92% YoY), while the FY2025 annual figure was $16.6 million, up 42.61% from the prior year.
- Payables for Q1 2026 stood at $10.8 million, down from $16.6 million in the prior quarter.
- The five-year high for Payables was $17.4 million in Q2 2025, with the low at $4.4 million in Q4 2022.
- The 5-year median for Payables is $10.0 million (2023), against an average of $9.8 million.
- The sharpest annual moves came in 2022 and 2025: Payables fell 25.72% in 2022, then surged 182.28% in 2025.
- Syndax Pharmaceuticals' Payables stood at $4.4 million in 2022, then surged by 128.99% to $10.0 million in 2023, then grew by 16.72% to $11.6 million in 2024, then jumped by 42.61% to $16.6 million in 2025, then sank by 34.6% to $10.8 million in 2026.
- Business Quant data shows SNDX's Payables at $10.8 million in Q1 2026, $16.6 million in Q4 2025, and $13.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Syndax Pharmaceuticals | 1.77 Bn | 1.22 Bn | 60.67 Mn | 4.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.87 Mn |
| Mar 31, 2026 | 10.84 Mn |
| Dec 31, 2025 | 16.58 Mn |
| Sep 30, 2025 | 13.83 Mn |
| Jun 30, 2025 | 17.35 Mn |
| Mar 31, 2025 | 10.05 Mn |
| Dec 31, 2024 | 11.63 Mn |
| Sep 30, 2024 | 4.90 Mn |
| Jun 30, 2024 | 11.57 Mn |
| Mar 31, 2024 | 8.81 Mn |
| Dec 31, 2023 | 9.96 Mn |
| Sep 30, 2023 | 6.05 Mn |
| Jun 30, 2023 | 10.98 Mn |
| Mar 31, 2023 | 8.06 Mn |
| Dec 31, 2022 | 4.35 Mn |
| Sep 30, 2022 | 7.12 Mn |
| Jun 30, 2022 | 6.44 Mn |
| Mar 31, 2022 | 8.23 Mn |
| Dec 31, 2021 | 5.86 Mn |
| Sep 30, 2021 | 5.12 Mn |